BioNTech SE
BioNTech SE is recorded as a service provider in 4 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 4 of 4 trials · Latest update first
A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX versus mFOLFIRINOX Alone in Patients with Resected Pancreatic Ductal Adenocarcinoma
Sponsor Genentech Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination with BNT116 (FixVac Lung) versus Cemiplimab Monotherapy in First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with Tumors Expressing PD-L1 ≥50%
Sponsor Regeneron Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors
Sponsor Genmab A/S
- Start (EU)
- Latest update
- Estimated end
A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination With Pembrolizumab Versus Pembrolizumab in Patients with Previously Untreated Advanced Melanoma
Sponsor Genentech Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for BioNTech SE?
The 2026-10-09 snapshot links BioNTech SE to 4 distinct CTIS trials. Recorded services include BIOMARKER ANALYSIS (Germany ONLY), Biomarker Manufacturing, Laboratory services, Specialty Lab. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for BioNTech SE?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Gastroenterology. Recorded phases include Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to BioNTech SE conducted?
The linked trials record locations in 8 countries, including Germany, Spain, France, Belgium, Denmark. These are trial locations, not confirmed office locations or countries where BioNTech SE delivered services.
What can this page tell me about BioNTech SE's trial experience?
Browse 4 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under BioNTech SE. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- BioNTech SE